Translations:Eicosapentaenoic acid/2/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
FuzzyBot (talk | contribs)
Importing a new version from external source
Tags: Mobile edit Mobile web edit
 
(No difference)

Latest revision as of 20:05, 14 April 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Eicosapentaenoic acid)
EPA is a [[polyunsaturated fatty acid]] (PUFA) that acts as a precursor for [[prostaglandin-3]] (which inhibits [[platelet aggregation]]), [[thromboxane-3]], and [[leukotriene-5]] [[eicosanoid]]s. EPA is both a precursor and the [[Hydrolysis|hydrolytic]] [[Metabolism|breakdown]] product of eicosapentaenoyl ethanolamide (EPEA: [[Carbon|C]]<sub>22</sub>[[Hydrogen|H]]<sub>35</sub>[[Biological functions of nitric oxide|NO]]<sub>2</sub>; 20:5,n-3).  Although studies of [[fish oil]] supplements, which contain both [[docosahexaenoic acid]] (DHA) and EPA, have failed to support claims of preventing [[Myocardial infarction|heart attacks]] or [[stroke]]s, a recent multi-year study of Vascepa ([[Ethyl group|ethyl]] [[eicosapentaenoate]], the [[Ethyl group|ethyl]] [[ester]] of the [[free fatty acid]]), a prescription drug containing only EPA, was shown to reduce heart attack, stroke, and cardiovascular death by 25% relative to a placebo in those with statin-resistant hypertriglyceridemia.

EPA is a polyunsaturated fatty acid (PUFA) that acts as a precursor for prostaglandin-3 (which inhibits platelet aggregation), thromboxane-3, and leukotriene-5 eicosanoids. EPA is both a precursor and the hydrolytic breakdown product of eicosapentaenoyl ethanolamide (EPEA: C22H35NO2; 20:5,n-3). Although studies of fish oil supplements, which contain both docosahexaenoic acid (DHA) and EPA, have failed to support claims of preventing heart attacks or strokes, a recent multi-year study of Vascepa (ethyl eicosapentaenoate, the ethyl ester of the free fatty acid), a prescription drug containing only EPA, was shown to reduce heart attack, stroke, and cardiovascular death by 25% relative to a placebo in those with statin-resistant hypertriglyceridemia.